Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: enzastaurin Clear all
Completed Phase 2 Interventional Results available

Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy

NCT00428714
View directory record Official record
Conditions
Prostate Cancer
Interventions
enzastaurin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
11
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 17, 2026, 9:34 PM EDT
Completed Phase 3 Interventional

A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

NCT03776071
View directory record Official record
Conditions
Glioblastoma
Interventions
Enzastaurin Hydrochloride, Placebo, Temozolomide, Radiotherapy
Drug · Other · Radiation
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 17, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients

NCT00466440
View directory record Official record
Conditions
Prostate Cancer
Interventions
enzastaurin, placebo, docetaxel, prednisone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
22
States / cities
Fullerton, California • Los Angeles, California • Northridge, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 17, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00308750
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
enzastaurin, pemetrexed, docetaxel, carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Burlington, North Carolina • Chapel Hill, North Carolina • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 17, 2026, 9:34 PM EDT
Completed Phase 3 Interventional

Enzastaurin Versus Lomustine in Glioblastoma

NCT00295815
View directory record Official record
Conditions
Glioblastoma
Interventions
enzastaurin, lomustine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
42
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 17, 2026, 9:34 PM EDT
Suspended Phase 3 Interventional

Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.

NCT05463679
View directory record Official record
Conditions
Vascular Ehlers-Danlos Syndrome
Interventions
Enzastaurin, Placebo
Drug
Lead sponsor
Aytu BioPharma, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 17, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy

NCT00533429
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
enzastaurin, pemetrexed, carboplatin, bevacizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
Bentonville, Arkansas • Chicago, Illinois • Galesburg, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 17, 2026, 9:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer

NCT00452413
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Malignant Solid Tumor
Interventions
enzastaurin, erlotinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 17, 2026, 9:34 PM EDT
Completed Phase 1 Interventional

Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer

NCT00550927
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bevacizumab, enzastaurin hydrochloride, diagnostic laboratory biomarker analysis, pharmacological study
Biological · Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 17, 2026, 9:34 PM EDT
Completed Phase 2 Interventional

Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.

NCT00105092
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Enzastaurin HCL
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Tampa, Florida • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2007 · Synced Oct 17, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma

NCT00718419
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia, Multiple Myeloma
Interventions
Enzastaurin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 17, 2026, 9:34 PM EDT
Completed Phase 1 Interventional

A Study of Enzastaurin in Patients With Leukemia

NCT00452257
View directory record Official record
Conditions
Leukemia, Lymphocytic
Interventions
enzastaurin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2009 · Synced Oct 17, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00407758
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
enzastaurin hydrochloride
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
16
States / cities
Los Angeles, California • Chicago, Illinois • Decatur, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 17, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer

NCT00437268
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumor
Interventions
enzastaurin, irinotecan, cetuximab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
20
States / cities
Casa Grande, Arizona • Tucson, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 17, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas

NCT00586508
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
enzastaurin, bevacizumab, Enzyme-inducing antiepileptic drugs (EIAED), Non-enzyme inducing antiepileptic drugs (NEIAED)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 17, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™

NCT03263026
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Enzastaurin Hydrochloride, R-CHOP + placebo
Drug · Other
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
27
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 17, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma

NCT00744991
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma
Interventions
Enzastaurin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 17, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Results available

PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

NCT00332202
View directory record Official record
Conditions
Non Hodgkin Lymphoma
Interventions
enzastaurin, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
24
States / cities
Anchorage, Alaska • Los Angeles, California • Orlando, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 17, 2026, 9:34 PM EDT
Completed Phase 1 Interventional

LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors

NCT00052273
View directory record Official record
Conditions
Adult, Solid Tumor
Interventions
capecitabine, enzastaurin hydrochloride
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 17, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only

NCT00451178
View directory record Official record
Conditions
Lymphoma
Interventions
enzastaurin, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
25
States / cities
Huntsville, Alabama • Beverly Hills, California • Greenbrae, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 17, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer

NCT00267020
View directory record Official record
Conditions
Pancreatic Neoplasm
Interventions
enzastaurin, gemcitabine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 17, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

A Study for Patients With Non-Hodgkin's Lymphomas

NCT00542919
View directory record Official record
Conditions
T-Cell Lymphoma, B-Cell Lymphoma
Interventions
enzastaurin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 17, 2026, 9:34 PM EDT
Completed Phase 2 Interventional

Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy

NCT00386087
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Enzastaurin Hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Newark, Delaware • Indianapolis, Indiana • South Bend, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2008 · Synced Oct 17, 2026, 9:34 PM EDT
Terminated Phase 1 Interventional

Enzastaurin to Treat Recurrent Brain Tumor

NCT00108056
View directory record Official record
Conditions
Glioma
Interventions
Enzastaurin (LY317615) monohydronchloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 17, 2026, 9:34 PM EDT